¿¬±¸µ¿ÇâÁ¤º¸
   
±Û¼ö : 658  
¹øÈ£ Á¦¸ñ ±Û¾´ÀÌ ÀÛ¼ºÀÏ Á¶È¸
178  ¹éÇ÷º´(Leukemia) Çѱ¹Àӻ󿬱¸µ¿Çâ_KCT Issue Paper°ü¸®ÀÚ2019.02.071366
177 ³úÀÇ ¾Æ¹Ð·ÎÀÌµå º´¸®(cerebral amyloid pathology)¿Í Ä¡¸Å¹ßº´°ú °ü·Ã¼º : ¸ÞŸºÐ¼®...°ü¸®ÀÚ2019.01.181614
176 2018³â Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º Ä¡ÀÇÇÐ ¿¬±¸µ¿ÇâºÐ¼®°ü¸®ÀÚ2019.01.181306
175 2018³â Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º °£È£ÇÐ ¿¬±¸µ¿ÇâºÐ¼®°ü¸®ÀÚ2019.01.161979
174 2018³â Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º ¿¹¹æÀÇÇÐ/º¸°ÇÇÐ ¿¬±¸µ¿ÇâºÐ¼®°ü¸®ÀÚ2019.01.161455
173 2018³â Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Ç⠺м®°ü¸®ÀÚ2019.01.141799
172 2018³â Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º ±âÃÊÀÇÇÐ ¿¬±¸µ¿ÇâºÐ¼®°ü¸®ÀÚ2019.01.141574
171  º¸°ÇÀÇ·á½Å±â¼ú °æÀïȯ°æºÐ¼® ¹× ¼ºÀåÀü¸Á : ÀÇ·á¿ë ¼ö¼ú·Îº¿°ü¸®ÀÚ2019.01.081322
170  Å¸¹ÌÇ÷ç(Tamiflu) : µ¶°¨Ä¡·áÁ¦(¿À¼¿Å¸¹Ìºñ¸£Àλ꿰) ºÎÀÛ¿ë°ü¸®ÀÚ2018.12.313542
169 Èñ±Í¼º ¹éÇ÷º´- °ø°Ý¼º NK ¼¼Æ÷¹éÇ÷º´(Aggressive NK-cell leukemia)¿¡ ´ëÇÑ µ¿Á¾ Á¶...°ü¸®ÀÚ2018.12.132132
168 Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¹éÇ÷º´(Philadelphia chromosome-positive leukemias)À» °¡Áø...°ü¸®ÀÚ2018.12.062169
167 T315I º¯ÀÌ°¡ÀÖ´Â Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¹éÇ÷º´ÀÇ Ponatinib Ä¡·á vs. µ¿Á¾Áٱ⼼Æ÷...°ü¸®ÀÚ2018.12.031997
166 ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´¿¡ ´ëÇÑ Nilotinib vs ImatinibÀÇ Àå±â ÀÓ»óÈ¿°ú ºñ±³ : 5³â RCT ...°ü¸®ÀÚ2018.11.291492
165 À¯·´ LeukemiaNet Æä³ÎÀÇ ¸¸¼º °ñ¼ö¼º¹éÇ÷º´(Chronic Myeloid Leukemia) Ä¡·á ºÎÀÛ¿ë ...°ü¸®ÀÚ2018.11.281929
164 ±Þ¼º°ñ¼ö¼º¹éÇ÷º´(acute myeloid leukemia, AML)ÀÇ Ã¶ºÐ ų·¹ÀÌÆ®( (Iron chelation t...°ü¸®ÀÚ2018.11.231759
163 DPP4 (dipeptidyl peptidase-4) ¾ïÁ¦Á¦ÀÇ ½ÉÇ÷°üÁúȯ À§Çèºñ±³°ü¸®ÀÚ2018.11.201904
162 Á¦2Çü ´ç´¢º´ÀÇ Ç÷´ç°ü¸® ÃֽŠÁö°ß :2018³â ¹Ì±¹´ç´¢º´ÇÐȸ(ADA)¿Í À¯·´¿±ÇÕ ´ç´¢ÇÐ...°ü¸®ÀÚ2018.11.192658
161 ±Þ¼º Ãæ¼ö¿°ÀÇ Ç×»ýÁ¦ Ä¡·á¿Í ¼ö¼úÄ¡·á 5³â Àå±âÃßÀû ºñ±³°ü¸®ÀÚ2018.11.161593
160 2018³â ºÎÁ¤¸ÆÇÐȸ Áöħ : ºñÆǸ·¼º ½É¹æ¼¼µ¿ ȯÀÚÀÇ ³úÁ¹Áß ÃâÇ÷À§Çèµµ ¿¹Ãø ¹× ³ú°æ...°ü¸®ÀÚ2018.11.141780
159 ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ (Chronic Myeloid Leukemia, CML) Ä¡·á¿¡¼­ º¸½ºÆ¼´Õ (Bostinib)...°ü¸®ÀÚ2018.11.051937
  21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30